By targeting a diverse set of signaling pathways, we aspire to take our small molecules from our discovery platform to the clinic.

Our pipeline

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.

Wholly-owned U.S.
Wholly-owned
Collaboration
COMPOUND (PARTNER)
PHASE 1
PHASE 2
PHASE 3OR REGISTRATION TRIAL
APPROVED

BRAFTOVI™ + MEKTOVI®* (Ono, Pierre Fabre)

Disease state:

Advanced BRAF-mutant melanoma

     Target: BRAF + MEK

Approved

Approved in US

Binimetinib (Ono, Pierre Fabre)

Disease state:

Cancer

     Target: MEK

Phase 3

Encorafenib (Ono, Pierre Fabre)

Disease state:

Cancer

     Target: BRAF

Phase 3

Selumetinib (AstraZeneca)

Disease state:

Cancer and NF1

     Target: MEK

Phase 3

Ipatasertib (Genentech)

Disease state:

Cancer

     Target: AKT

Phase 3

Varlitinib (ASLAN)

Disease state:

Cancer

     Target: Pan-HER

Phase 3

Ganovo® (danoprevir, Roche / Ascletis)

Disease state:

Hepatitis C

     Target: NS3 Protease

Approved

Approved in China

ARRY-797

Disease state:

LMNA-related DCM

     Target: p38

Phase 3

Larotrectinib* (Loxo Oncology)

Disease state:

Cancer

     Target: PanTrk

Phase 3

Tucatinib* (Seattle Genetics)

Disease state:

Cancer

     Target: HER-2

Phase 3

ARRY-382

Disease state:

Cancer

     Target: CSF1R

Phase 2

Motolimod (Celgene)

Disease state:

Cancer

     Target: TLR

Phase 2

Prexasertib (Eli Lilly)

Disease state:

Cancer

     Target: Chk1

Phase 2

LOXO-292 (Loxo Oncology)

Disease state:

Cancer

     Target: Ret

Phase 2

GDC-0575 (Genentech)

Disease state:

Cancer

     Target: Chk1

Phase 1

LOXO-195 (Loxo Oncology)

Disease state:

Cancer

     Target: Trk

Phase 1

AK-1830 (Asahi Kasei Pharma)

Disease state:

Inflammation

     Target: Trk

Phase 1

*Phase 2 registration trials